DOI:
10.1055/s-00000134
Diabetologie und Stoffwechsel
LinksClose Window
References
Zinman B, Inzucchi SE, Lachin JM. et al.
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Cardiovasc Diabetol 2014;
13: 102
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.